{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:10:57Z","timestamp":1792174257666,"version":"4.4.0"},"reference-count":23,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>We report on the early clinical outcomes of a prospective series of early breast cancer (EBC) patients treated with ultra-hypofractionated post-operative whole-breast irradiation (WBI) after breast-conserving surgery (BCS) and axillary management. Primary endpoints were patient\u2019s compliance and acute toxicity. Secondary endpoints included physician-rated cosmesis and ipsilateral breast tumour recurrence (IBTR). Acute toxicity was evaluated at the end of WBI, 3 weeks and 6 months thereafter, according to the Common Terminology Criteria for Adverse Events (v. 5.0). Patients were treated between September 2021 and May 2022. The treatment schedule for WBI consisted of either 26 Gy in 5 fractions over one week (standard approach) or 28.5 Gy in 5 fractions over 5 weeks (reserved to elders). Inverse planned intensity-modulated radiation therapy (IMRT) was used employing a static technique. A total of 70 patients were treated. Fifty-nine were treated with the 26 Gy\/5 fr\/1 w and 11 with the 28.5 Gy\/5 fr\/5 ws schedule. Median age was 67 and 70 in the two groups. Most of the patients had left-sided tumours (53.2%) in the 26 Gy\/5 fr\/1 w or right-sided lesions (63.6%) in the 28.5 Gy\/5 fr\/5 ws group. Most of the patients had a clinical T1N0 disease and a pathological pT1pN0(sn) after surgery. Ductal invasive carcinoma was the most frequent histology. Luminal A intrinsic subtyping was most frequent. Most of the patients underwent BCS and sentinel lymph node biopsy and adjuvant endocrine therapy. All patients completed the treatment program as planned. Maximum detected acute skin toxicities were grade 2 erythema (6.7%), grade 2 induration (4.4%), and grade 2 skin colour changes. No early IBTR was observed. Ultra-hypofractionated WBI provides favourable compliance and early clinical outcomes in EBC after BCS in a real-world setting.<\/jats:p>","DOI":"10.3390\/biomedicines10102568","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T20:55:11Z","timestamp":1665694511000},"page":"2568","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Ultra-Hypofractionation for Whole-Breast Irradiation in Early Breast Cancer: Interim Analysis of a Prospective Study"],"prefix":"10.3390","volume":"10","author":[{"given":"Valeria","family":"Sigaudi","sequence":"first","affiliation":[{"name":"Department of Translational Medicine (DIMET), University of Eastern Piedmont, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micol","family":"Zannetti","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine (DIMET), University of Eastern Piedmont, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Ferrara","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Maggiore della Carit\u00e0 University Hospital, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Manfredda","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Maggiore della Carit\u00e0 University Hospital, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Mones","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Maggiore della Carit\u00e0 University Hospital, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Loi","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Maggiore della Carit\u00e0 University Hospital, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-8379","authenticated-orcid":false,"given":"Marco","family":"Krengli","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine (DIMET), University of Eastern Piedmont, 28100 Novara, Italy"},{"name":"Department of Radiation Oncology, Maggiore della Carit\u00e0 University Hospital, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2276-0687","authenticated-orcid":false,"given":"Pierfrancesco","family":"Franco","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine (DIMET), University of Eastern Piedmont, 28100 Novara, Italy"},{"name":"Department of Radiation Oncology, Maggiore della Carit\u00e0 University Hospital, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12032-013-0518-7","article-title":"Five-year results of a prospective case series of accelerated hypofractionated whole breast radiation with concomitant boost to the surgical bed after conserving surgery for early breast cancer","volume":"30","author":"Cante","year":"2013","journal-title":"Med. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG), Darby, S., McGale, P., Correa, C., Taylor, C., Arriagada, R., Clarke, M., Cutter, D., Davies, C., and Ewertz, M. (2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet, 378, 1707\u20131716.","DOI":"10.1016\/S0140-6736(11)61629-2"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"EBCTCG (Early Breast Cancer Trialists\u2019 Collaborative Group), McGale, P., Taylor, C., Correa, C., Cutter, D., Duane, F., Ewertz, M., Gray, R., Mannu, G., and Peto, R. (2014). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet, 383, 2127\u20132135.","DOI":"10.1016\/S0140-6736(14)60488-8"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/cncr.23646","article-title":"Radiation therapy for operable breast cancer: Sixty years of progress as seen through the articles published in the journal Cancer","volume":"113","author":"Freedman","year":"2008","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0906260","article-title":"Long-term results of hypofractionated radiation therapy for breast cancer","volume":"11","author":"Whelan","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Brunt","year":"2020","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1200\/JCO.19.02750","article-title":"Ten-year results of FAST: A randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer","volume":"38","author":"Brunt","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.clon.2021.04.016","article-title":"Five-fraction radiotherapy for breast cancer: FAST-Forward to implementation","volume":"33","author":"Brunt","year":"2021","journal-title":"Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.clon.2021.04.007","article-title":"Moving forward fast with FAST-Forward","volume":"33","author":"Lewis","year":"2021","journal-title":"Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Eckstein, J., Taylor, P., Zheng, R., Lee, L., Chen, W., Potters, L., and Evans, C. (2022). Implementation of external beam five-fraction adjuvant breast irradiation in a US center. Cancers, 14.","DOI":"10.3390\/cancers14061556"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The eight edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more \u2018personalized\u2019 approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_14","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program (2021, May 10). Common Toxicity Criteria for Adverse Events. 2017 Version 5.0, Available online: http:\/\/ctep.cancer.gov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/archsurg.1989.01410020023002","article-title":"Conservative surgery and radiation therapy for early-stage breast cancer: Long-term cosmetic results","volume":"124","author":"Rose","year":"1989","journal-title":"Arch. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S1470-2045(21)00539-8","article-title":"European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer","volume":"23","author":"Meattini","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/JCO.20.01363","article-title":"Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: The DBCG HYPO trial","volume":"38","author":"Offersen","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1470-2045(18)30813-1","article-title":"Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: A randomised, non-inferiority, open-label, phase 3 trial","volume":"20","author":"Wang","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.radonc.2012.06.002","article-title":"The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy","volume":"104","author":"Tsang","year":"2012","journal-title":"Radiother. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clon.2022.03.001","article-title":"From 25 fractions to five: How hypofractionation has revolutionised adjuvant breast radiotherapy","volume":"34","author":"Yarnold","year":"2022","journal-title":"Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.radonc.2011.06.026","article-title":"First results of the randomised UK FAST trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE\/04\/15)","volume":"100","author":"Agrawal","year":"2011","journal-title":"Radiother. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.clbc.2014.12.011","article-title":"Once-weekly hypofractionated whole breast radiotherapy after breast-conserving surgery in older patients: A potential alternative treatment schedule to daily 3-week hypofractionation","volume":"15","author":"Rovea","year":"2015","journal-title":"Clin. Breast Cancer"},{"key":"ref_23","first-page":"112","article-title":"Omission of postoperative radiation after breast conserving surgery: A progressive paradigm shift towards precision medicine","volume":"21","author":"Franco","year":"2020","journal-title":"Clin. Transl. Radiat. Oncol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/10\/2568\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:53:41Z","timestamp":1760144021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/10\/2568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["biomedicines10102568"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10102568","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,13]]}}}